



XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference

Oral presentation will be held on September 13, 2007 at the 14th International Symposium on Hepatitis C Virus & Related Viruses to be held in Glasgow, Scotland

Valley Cottage, New York, September 6, 2007 – XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, LSE: XTL, TASE: XTL) announced today that a late breaker abstract, entitled “Potent Small Molecule HCV Inhibitors Affecting NS5A-dependent Functions,” was selected for oral presentation at the 14th International Symposium on Hepatitis C Virus & Related Viruses (www.hcv2007.com).

The presentation will take place at 10:30 Greenwich Mean time on Thursday, September 13, 2007, and a press release outlining the data presented will be released by the Company shortly thereafter.

The compounds that will be presented at the conference emerged from the Company’s DOS program, aimed at discovering novel hepatitis C inhibitors applying a unique chemistry technology called Diversity Oriented Synthesis. The DOS program was acquired by the Company in late 2005.

ABOUT XTL BIOPHARMACEUTICALS LTD.

XTL Biopharmaceuticals Ltd. (“XTL”) is engaged in the development of therapeutics for the treatment of neuropathic pain and hepatitis C. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of diabetic neuropathic pain. XTL is also developing several novel pre-clinical hepatitis C small molecule inhibitors. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ, London, and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).

Contact:

Ron Bentsur, Chief Executive Officer
Tel: +1-(845)-267-0707 ext. 225